Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ: ALVO) announced on April 30, 2026 that General Counsel Tanya Zharov has asked to step down after six years and will remain during a multi-month handover. The company named Lisa Graver taking over the CEO role and noted some executive relocations to Reykjavik.
The release says Zharov will assume responsibilities for chairman Róbert Wessman’s holding companies, Aztiq and Flóki, while supporting Alvotech during transition.
Alvotech (NASDAQ: ALVO) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after U.S. market close. A webcast with live Q&A is scheduled for Thursday, May 7, 2026 at 08:00 EST (12:00 GMT).
Slides and presentation materials will be posted on the company's investor events page before the call. Registration links and investor/media contact emails are provided for access and inquiries.
Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026. The filing incorporates parts of the Alvotech Annual Report 2025 and is publicly available on the SEC website and Alvotech investor relations site.
For investor or media inquiries, Alvotech provided contact emails for media and investor relations on its investor site.
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026. The report is available in the company's investor relations website and is attached to the announcement in PDF and iXBRL formats. Contact details for media and investors are provided for further inquiries.
Alvotech (NASDAQ: ALVO) reported Q4 2025 revenues of $173M (+13% YoY) and FY 2025 revenues of $593M (+21% YoY). Adjusted EBITDA was $69M in Q4 and $137M for FY 2025 (+27% YoY). Cash on Dec 31, 2025 was $172M. Multiple biosimilar approvals and commercial deals were announced; management reaffirmed 2026 guidance of $650–700M revenue and $180–220M adjusted EBITDA.
Company cited regulatory observations from an FDA inspection and plans to resubmit affected applications in Q2 2026 while expanding partnerships and acquisitions.
Alvotech (NASDAQ: ALVO) will report its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026 after U.S. markets close.
The company will host a conference call with live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). Slides and materials will be posted on the investor website before the call, and registration is required to access the webcast and Q&A.
Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share. The notices reflect an intra‑group transfer between ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l.
Contact provided: Benedikt Stefansson, VP investor relations, valvotech.ir@alvotech.com.
Alvotech (NASDAQ: ALVO) increased share capital by USD 125,000 through issuance of 12,500,000 ordinary shares at USD 5.20 per share to its subsidiary Alvotech Manco ehf.
The subsidiary's holding rises to 16,254,005 shares (4.7%); total issued shares increased from 334,038,147 to 346,538,147. Outstanding shares remain 330,284,142. The increase supports settlement of a prior stock lending facility and the company's obligations for warrants, convertibles, and employee programs.
Alvotech (NASDAQ: ALVO) reported positive top-line results from the pivotal PK study AVT80-GL-P01 comparing AVT80 to Entyvio (vedolizumab). The randomized, double-blind, single-dose, 3-arm study met all primary endpoints for PK similarity and assessed safety, tolerability and immunogenicity in healthy adults.
The company said the study is considered pivotal to support regulatory submissions for both subcutaneous AVT80 and intravenous AVT16. Entyvio global net sales were about US$6.4 billion in 2025.
Alvotech (NASDAQ: ALVO) entered supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada and Australia & New Zealand (announced February 2, 2026). The deals cover one ophthalmology candidate in Canada and three immunology/gastroenterology candidates in Australia/New Zealand.
Sandoz will lead regulatory filings, commercialization and distribution; Alvotech will retain development, global clinical activities and manufacturing and will supply finished product under exclusive supply arrangements.